Acción 300702 ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Zhejiang Tianyu Pharmaceutical Co., Ltd.

Acciones

300702

CNE1000034X1

Precio de cierre Shenzhen S.E.
Otros sitios de cotización
 00:00:00 17/05/2024 		Varia. Cinco días. Varia. 1 de enero.
20,49 CNY -0,97 % Gráfico intradía de Zhejiang Tianyu Pharmaceutical Co., Ltd. -1,40 % -5,62 %
06/05 China aprueba el medicamento cardiaco de Tianyu Pharma MT
25/04 Zhejiang Tianyu Pharmaceutical Co. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
China Approves Tianyu Pharma's Heart Medication
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024.
Zhaoxin Liaowang No. 1 Private Securities Investment Fund managed by Jiangsu Zhaoxin Private Fund Management Co., Ltd. entered into a share transfer agreement to acquire 6.19% stake in Zhejiang Tianyu Pharmaceutical Co., Ltd. from Ganzhou Zhenhan Venture Capital Co., Ltd. for CNY 310 million.
Zhejiang Tianyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.
Zhejiang Tianyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Tianyu Pharmaceutical Unit Passes US FDA's On-Site Inspection
Tianyu Pharma Unit Passes US FDA On-Site Inspection
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug
Raw Drug Material of Tianyu Pharma's Unit Passes Regulatory Evaluation
Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.4 billion in funding
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Management Changes
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang Tianyu Pharma Unit Gets Marketing Approval For Losartan Potassium Tablets
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 300702
  4. Noticias Zhejiang Tianyu Pharmaceutical Co., Ltd.
  5. Otros idiomas